About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
BLUE - bluebird bio| Previous Close | $52.89 | Open | $52.83 |
| Volume | 623.2K | Market Cap | 3.503B |
| Yield | Last Dividend |
| CAR T Cell Therapy Market Future Opportu... | 10/22/20 |
| The ???CAR T Cell Therapy Market??? Research Report is a resource, which provides current as well as upcoming technical and financial details of the i... | |
| bluebird bio (NASDAQ:BLUE) Earns Buy Rat... | 10/21/20 |
| Mizuho started coverage on shares of bluebird bio (NASDAQ:BLUE) in a research note published on Monday, Anlyst Ratings reports. The brokerage issued a... | |
| Zacks: Analysts Anticipate bluebird bio,... | 10/21/20 |
| Wall Street brokerages expect that bluebird bio, Inc. (NASDAQ:BLUE) will report ($3.09) earnings per share (EPS) for the current fiscal quarter, Zacks... | |
| bluebird bio (NASDAQ:BLUE) Now Covered b... | 10/21/20 |
| Mizuho began coverage on shares of bluebird bio (NASDAQ:BLUE) in a report released on Monday, AR Network reports. The brokerage set a ???buy??? rating... | |
| Top Analyst Upgrades and Downgrades: AEP... | 10/20/20 |
| Tuesday's top analyst upgrades and downgrades included American Electric Power, Apache, AT&T, ConocoPhillips, Bluebird Bio, Fortinet, Intel, IBM, Kind... | |
| bluebird bio (NASDAQ:BLUE) Coverage Init... | 10/19/20 |
| Mizuho started coverage on shares of bluebird bio (NASDAQ:BLUE) in a research note released on Monday morning, The Fly reports. The firm issued a buy ... | |
| CAR T Cell Therapy Market size (sales, r... | 10/13/20 |
| CMI Research added a comprehensive research document of 200+ pages on the ???CAR T Cell Therapy Market??? with detailed insights on growth factors and... | |
| bluebird bio Announces European Medicine... | 10/02/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio announces EMA's acceptance of Marketing Authorization Application (MAA) for elivaldogene autotemcel ge... | |
| bluebird bio to Present at Jefferies Cel... | 09/28/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Jeffe... | |
| bluebird bio???s LentiGlobin??? for Sick... | 09/23/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced today that its investigational treatment for sickle cell disease (SCD),... | |
| Is bluebird bio Stock a Buy? | 09/09/20 |
| bluebird bio hasn't performed well in the stock market of late. Do the biotech's recent woes make this a good opportunity for investors to buy its sha... | |
| bluebird bio Announces September Investo... | 09/02/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the follo... | |
| bluebird bio Presents New Results from C... | 08/29/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced updated results from the clinical development program for its investiga... | |
| bluebird bio : Corporate Presentation Q3... | 08/18/20 |
| Actively engaging to enable access & value-based payment over time at launch Policy - Focused on enabling value-based payment over time in commercial ... | |
| bluebird bio Appoints Denice Torres to B... | 08/11/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has appointed Denice Torres to its Board of Directors. ??... | |
| Why Bluebird Bio's Stock Is Trading High... | 08/06/20 |
| Bluebird Bio (NASDAQ: BLUE ) shares are trading higher on Thursday after the company reported second-quarter EPS and sales results up from last year. ... | |
| Why Bluebird Bio's Stock Is Trading High... | 08/06/20 |
| Bluebird Bio (NASDAQ: BLUE) shares are trading higher on Thursday after the company reported second-quarter EPS and sales results up from last year. W... | |
| bluebird bio Reports Second Quarter 2020... | 08/05/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the second quarter e... | |
| bluebird bio Announces August Investor E... | 07/31/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) today announced members of the management team will participate in the Canaccord ... | |
| The Daily Biotech Pulse: Bristol-Myers, ... | 07/30/20 |
| Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) Abbott Laboratories (NYSE: ABT) ABIOMED, Inc. (NASDAQ: ABMD) Adamis Pharmaceuticals C... | |
| Bristol Myers Squibb and bluebird bio An... | 07/29/20 |
| PRINCETON, N.J., & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $BLUE #BMS--BMS and bluebird bio Announce Submission of Biologics License Application (BLA) t... | |
| Buy rating | 10/20/20 |
| Mizuho initiates coverage with Buy rating and announces Price Target of $123.00 | |
| Hold rating | 08/10/20 |
| Morgan Stanley maintains Equal-Weight rating and lowers Price Target from $73.00 to $68.00 | |
| Strong Buy rating | 08/06/20 |
| Wedbush maintains Outperform rating and lowers Price Target from $89.00 to $81.00 | |
| Strong Buy rating | 08/06/20 |
| BMO Capital maintains Outperform rating and lowers Price Target from $112.00 to $108.00 | |
| Date | 2020-08-05 (AMC) | Est. (EPS/Rev.) | ($2.60)/ 66.7M |
| Actual (EPS/Rev.) | $-0.36/ $198.89 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Swingtrades | R. belegger | 83.00 % | Follow |
| Stocks and Options Elite | Calvin Moore | 75.00 % | Subscribe |
| Analyst Rating Investments | BigMoveTrader | 68.00 % | Follow |
| Lewis Aung's long pick | Kyaw Aung | 66.00 % | Subscribe |
| LavaPit | Steve Pitkin | 57.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
